| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |